Insmed Inc (INSM)vsXOMA Corp (XOMA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
XOMA
XOMA Corp
$29.22
-1.85%
HEALTHCARE · Cap: $355.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1063% more annual revenue ($606.42M vs $52.15M). XOMA leads profitability with a 60.8% profit margin vs -2.1%. XOMA earns a higher WallStSmart Score of 57/100 (C).
INSM
Hold39
out of 100
Grade: F
XOMA
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-356.3%
Fair Value
$5.10
Current Price
$29.22
$24.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 34 in profit
Keeps 61 of every $100 in revenue as profit
Revenue surging 57.9% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Elevated debt levels
Earnings declined 47.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : XOMA
The strongest argument for XOMA centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 60.8% and operating margin at 15.9%. Revenue growth of 57.9% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : XOMA
The primary concerns for XOMA are P/E Ratio, Market Cap, Debt/Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while XOMA is a growth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
XOMA is growing revenue faster at 57.9% — sustainability is the question.
XOMA generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
XOMA scores higher overall (57/100 vs 39/100), backed by strong 60.8% margins and 57.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
XOMA Corp
HEALTHCARE · BIOTECHNOLOGY · USA
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?